Bevacizumab combined with chemotherapy for patients with advanced colorectal cancer: a systematic review

摘要

Background: Fluoropyrimidine-based chemotherapy is considered standard treatment of advanced colorectal cancer. Recent studies indicate benefit to the addition of bevacizumab, a recombinant monoclonal antibody targeting vascular endothelial growth factor.